Trials / Completed
CompletedNCT00366288
Study Evaluating PAZ-417 in Healthy Young/Elderly
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAZ-417 Administered Orally to Healthy Young and Healthy Elderly Subjects
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 56 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects. The effect of a high fat meal on the metabolism of PAZ-417 will also be studied, along with blood levels of PAZ-417 . Changes in cognitive function will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PAZ-417 | 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly. |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2006-08-21
- Last updated
- 2009-07-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00366288. Inclusion in this directory is not an endorsement.